U.S. Luxury Stock News

Porch Group (PRCH) just released its third quarter results, catching investors’ attention with higher sales year over year but a swing from net income to a net loss compared to last year’s figures. See our latest analysis for Porch Group. Investors have clearly reacted to the fresh earnings results, sending Porch Group’s share price up 9.24% in just one day and capping off a 222.42% year-to-date share price return. Momentum has picked up dramatically this year, with a staggering 600.00% total...

In the past week, Ball Corporation reported third quarter 2025 results with revenue rising to US$3.38 billion and net income increasing to US$321 million, alongside a continued cash dividend and the addition of Solenis CEO John E. Panichella to its board of directors. A key insight is Ball's reaffirmed focus on returning capital to shareholders, substantial progress in sustainable packaging, and strong long-term contractual visibility, all supporting confidence in its outlook despite input...

trivago (TRVG) remains unprofitable, but losses have narrowed at an average rate of 9% per year over the past five years. Revenue is forecast to grow at 9.9% per year, trailing the US market average of 10.5%. Earnings are expected to accelerate, with forecasts pointing to 53.76% annual growth and the company turning profitable within three years. With a Price-to-Sales Ratio of 0.4x compared to the industry average of 1.4x and shares trading at $3.09 versus a fair value estimate of $10.08,...

Crexendo (CXDO) is forecasting robust annual earnings growth of 27.33%, well ahead of the US market’s 16% pace. Revenue is expected to climb by 10.8% each year, outstripping the national average of 10.5%. However, net profit margins dipped slightly to 4.7% from last year’s 4.9%. This comes as the company reversed a five-year trend of earnings declines by posting 9.7% growth over the past twelve months. Investors will note that shares are trading below estimated fair value and analyst targets,...

GXO Logistics (GXO) reported net profit margins of 0.5%, down from 1.4% a year ago, as a one-off loss of $171 million weighed heavily on the bottom line. Despite the negative earnings growth and near-term margin pressure, the company has delivered an average annual earnings growth of 8.7% over the past five years. Looking ahead, forecasts suggest a robust 53.49% per year earnings growth, easily outpacing the broader US market’s expected 16%, with shares currently trading at $52.54 and a...

Wondering if Archer Aviation is a hidden gem or flying too close to the sun? You are not alone. With all the recent buzz, it's natural to ask if the stock is truly worth its current price. After soaring an incredible 198.1% over the last year and posting a massive 284.3% gain in three years, the stock has pulled back significantly in the past month, dropping 29.8%. These price swings have been fueled by headlines about Archer Aviation's partnerships in the electric air taxi sector and...

Wondering if Arlo Technologies is a hidden gem or priced just right? You are not alone, especially with all eyes on where tech stocks land on the value spectrum. While Arlo's shares have soared 61.4% year-to-date and gained an impressive 50.5% over the past year, there have been bumps along the way, including a recent 8.4% dip in the last week. News around heightened demand for smart home security and Arlo's latest expansion of its product lineup have kept the stock in the...

Wondering if Clearwater Analytics Holdings is attractively priced, or if there is hidden value waiting to be uncovered? You are not alone, and making the right call on valuation can make a significant difference. After a sluggish year with the stock down 39.4%, recent price moves suggest that investor sentiment may be shifting. However, there is still plenty of debate about the outlook. Market watchers have noted that recent partnerships and expanded integrations with financial institutions...

On October 28, 2025, Calm Health announced a partnership with LifeStance Health Group, allowing Calm Health users to access LifeStance's mental health services directly through the app when higher-acuity care is needed. This collaboration creates a streamlined connection from digital mental health screening to personalized in-person or virtual care, potentially lowering barriers for individuals seeking timely, evidence-based support. We'll examine how integrating Calm Health's digital...

On November 5, 2025, e.l.f. Beauty reported its second-quarter financial results and provided updated earnings guidance for fiscal year 2026, forecasting net sales between US$1.55 billion and US$1.57 billion and full-year net sales growth of 18% to 20%. Despite strong sales growth, the company's net income and earnings per share declined for both the quarter and six-month period compared to the previous year, emphasizing margin pressures amid higher costs and ongoing tariff challenges. We’ll...

Lindsay Corporation recently announced a new share repurchase program authorizing up to US$150 million in common stock buybacks with no expiration date, following the completion of a previous buyback initiative. This move underscores the company's ongoing focus on capital returns and signals management’s continued confidence in Lindsay’s long-term outlook. We’ll explore how the newly unveiled buyback plan strengthens Lindsay’s investment narrative, especially regarding its approach to...

Champion Homes (SKY) posted a standout year, with earnings rising 53.8%, noticeably above its 5-year annual average of 8%. Net profit margin also strengthened to 8.5%, up from 6.5% a year ago, and the share price is trading just under a discounted cash flow estimate of fair value at $73.22 per share. While growth expectations for both revenue and earnings remain steady, investors are likely to focus on the combination of improved margins, continued earnings quality, and the company’s track...

If you have ever wondered whether Gap stock is a bargain right now, you are not alone. Let us break down what is going on beneath the surface. The share price has seen some turbulence lately, slipping 1.1% over the last week but climbing 8.9% in the past month. It has also shown a solid 12.3% return over the last year and an impressive 148.1% jump in the last three years. Recent headlines have focused on Gap's brand reinvention efforts and leadership changes, which have sparked fresh...

In late October 2025, Tubi Media Group announced a multi-year deal with Audiochuck for exclusive distribution and advertising rights on popular true crime podcasts, expanding Fox's streaming and podcast offerings through Tubi and FOX One platforms, alongside an update on Fox’s share repurchase program and its release of first quarter earnings showing increased sales but a lower net income year-over-year. This collaboration leverages Audiochuck’s top-ranked podcasts, including Crime Junkie,...

Ever wondered whether Prologis is a "buy" right now? You're not alone. Getting the valuation right could be the difference between catching the next wave and missing out. Recently, Prologis shares have gained 5.7% over the past month and are up an impressive 18.8% year-to-date. This suggests renewed optimism among investors and growing interest in its growth potential. This uptick comes after Prologis made headlines with a major expansion of its logistics network and several high-profile...

In recent days, Stephens initiated coverage on Twist Bioscience, highlighting the company's proprietary silicon chip technology and operational strengths, while Element Biosciences and Twist Bioscience announced a new collaboration to advance sequencing solutions. This partnership aims to improve sample processing speed for next-generation sequencing, signaling Twist Bioscience's ongoing commitment to product innovation and market expansion. We'll examine how the new sequencing collaboration...

Acacia Research (ACTG) remains unprofitable, with losses deepening at an annual rate of 13.4% over the past five years. Net profit margin has failed to improve and profitability measures show little positive change, keeping the company firmly on the back foot this season. With no signs of expected revenue or earnings growth, investors are left weighing persistent losses against a current Price-To-Sales Ratio of 1.4x, which is well below industry and peer averages. See our full analysis for...

Edison International reported its third quarter and nine-month results for 2025, showing sales of US$5.75 billion and US$14.10 billion respectively, with net income rising to US$832 million for the quarter and US$2.61 billion year-to-date. This period saw a very large increase in net income compared to the previous year, reflecting significant growth in profitability amid only moderate sales gains. With this sharp increase in quarterly earnings, we’ll now assess what this means for Edison...

In the past week, Align Technology reported stronger-than-expected third-quarter results, highlighted robust global demand for its Clear Aligner products, and unveiled a range of digital dental innovations including workflow enhancements for iTero scanners and a new rapid treatment planning system called ClinCheck Live Plan. These developments signal Align's focus on accelerating dental practice efficiency and patient engagement while maintaining product innovation amid growing international...

Bristow Group (VTOL) posted a standout earnings update, transitioning to profitability with earnings growing at 27.7% per year over the past five years. Its latest net profit margin surged to 8.2%, far outstripping last year’s 2.2%. The most recent annual earnings jumped an impressive 282.6%, which is well above the five-year trend and supports the view that Bristow is delivering high quality earnings. The stock’s Price-to-Earnings ratio sits at 9.4x, notably below both the US Energy Services...

In early November 2025, Bristol-Myers Squibb reported quarterly earnings that surpassed analyst expectations and raised its revenue guidance for the year, while commencing a multi-billion euro debt financing to support a tender offer for outstanding notes and ongoing corporate needs. Recent clinical advances and collaborations, such as updated Sotyktu data, progress in CAR T-cell therapy, and supply agreements, highlight the company’s ongoing focus on innovation in immunology and hematology,...

Wondering if Devon Energy might be undervalued, or if its stock still offers a hidden bargain? You are not alone, as many investors are looking to decode the real value behind this well-known energy name. The stock has seen some ups and downs recently, gaining 0.9% over the past week but down 7.4% in the last month. Over the past year, it has fallen 16.9%, even as its five-year return sits at an impressive 259.6%. Much of Devon Energy's recent movement has been driven by shifting oil prices...

Wondering if AeroVironment is a smart buy or heading for turbulence? If you are curious about whether the recent buzz matches the stock’s true value, you are in good company. The stock grabbed attention with a 124.2% year-to-date gain, even after pulling back 7.9% over the last week and 10.5% over the past month. Recent headlines have focused on AeroVironment’s continued role in supplying advanced drone technology to defense clients, with new contracts fueling investor optimism. As drone and...

Nurix Therapeutics (NRIX) is gearing up to present fresh clinical data from its NX-5948-301 Phase 1a/1b trial at the upcoming American Society of Hematology Annual Meeting. Investors are watching these updates for insight into the company’s research progress. See our latest analysis for Nurix Therapeutics. With anticipation building around Nurix’s upcoming clinical data releases, the stock has staged a swift comeback lately, gaining 25% in the past month alone. Still, momentum is only just...